AnalysisBoxoffy Intelligence
Boxoffy · Box Office Intelligence · Updated March 2026
Sivakarthikeyan reinvests his acting fees directly into production — aligned incentives and complete creative control. Thaai Kizhavi (2026) is the year's content surprise — a no-star Tamil film that's crossed ₹50 Cr India net in Week 10, outperforming most star-led releases in longevity. Doctor during COVID (2021) proved the model works even in impossible exhibition conditions.
Boxoffy Note
Sivakarthikeyan is simultaneously Tamil cinema's most bankable mid-range star and its most disciplined independent producer — a combination that is exceedingly rare in Indian cinema.
ProfileStudio Profile
Founded
2018
Founder
Sivakarthikeyan · Sudhan Sundaram
Current Head
Sivakarthikeyan
Headquarters
Chennai
Languages
Tamil
Tier
BOUTIQUE
OTT Partner
JioHotstar
FilmographyKey Films
Doctor
Ayalaan
Thaai Kizhavi
Pipeline2026 Slate & Upcoming
Thaai Kizhavi — RUNNING (Week 3, Mar 2026) · ₹4.8 Cr this week · Exceptional long-tail performer for a no-star Tamil drama
Sivakarthikeyan's next directorial/production — TBA 2026/2027 · Expected to return to grounded storytelling after Kanguva-era scale experiments · Promo shoot reportedly beginning soon for next SK film
Multiple Tamil 2026 projects — TBA · Passion Studios developing parallel slate independent of SK's acting commitments
FinanceEstimated Market Valuation
₹200–500 Cr
ESTIMATED
Estimated · Early-stage; Thaai Kizhavi + Doctor IP base; entirely self-funded
Corporate StructurePrivate Limited Company
ListedNo — private. Entirely self-funded from Sivakarthikeyan acting fees
Revenue ReferenceNot disclosed. Fully self-funded model
CorporateOwnership & Corporate Structure
Sivakarthikeyan
Co-Founder & Primary Shareholder
Funds from acting fees reinvested into production
Majority
Sudhan Sundaram
Co-Founder
Business operations partner
Minority